Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Carboplatin
/ administration & dosage
Cisplatin
/ administration & dosage
Clinical Trials as Topic
Female
Head and Neck Neoplasms
/ drug therapy
Humans
Japan
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
/ drug therapy
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Survival Analysis
Treatment Outcome
EXTREME regimen
R/M SCCHN
nivolumab
platinum-refractory disease
post-progression survival
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
16
10
2019
revised:
13
11
2019
accepted:
14
11
2019
entrez:
8
12
2019
pubmed:
8
12
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
This Japanese multiple-center retrospective study aimed to examine the real-world treatment outcomes of the EXTREME regimen as a first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A total of 100 R/M SCCHN patients treated with the EXTREME regimen as first-line therapy were analyzed. The treatment outcomes were evaluated to compare patient and treatment characteristics with overall survival. Patients treated with carboplatin-based EXTREME regimen showed similar overall survival with less adverse effects compared to that of patients using cisplatin. The post-progression survival was significantly longer in patients treated with second-line treatment following the EXTREME regimen than in those without second-line treatment. The carboplatin-based EXTREME regimen was more feasible with similar treatment outcomes compared to cisplatin-based EXTREME regimen. In addition, subsequent lines of therapy contributed to improvement of survival for R/M SCCHN patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
This Japanese multiple-center retrospective study aimed to examine the real-world treatment outcomes of the EXTREME regimen as a first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
PATIENTS AND METHODS
METHODS
A total of 100 R/M SCCHN patients treated with the EXTREME regimen as first-line therapy were analyzed. The treatment outcomes were evaluated to compare patient and treatment characteristics with overall survival.
RESULTS
RESULTS
Patients treated with carboplatin-based EXTREME regimen showed similar overall survival with less adverse effects compared to that of patients using cisplatin. The post-progression survival was significantly longer in patients treated with second-line treatment following the EXTREME regimen than in those without second-line treatment.
CONCLUSION
CONCLUSIONS
The carboplatin-based EXTREME regimen was more feasible with similar treatment outcomes compared to cisplatin-based EXTREME regimen. In addition, subsequent lines of therapy contributed to improvement of survival for R/M SCCHN patients.
Identifiants
pubmed: 31810948
pii: 39/12/6819
doi: 10.21873/anticanres.13898
doi:
Substances chimiques
Antineoplastic Agents
0
Carboplatin
BG3F62OND5
Cisplatin
Q20Q21Q62J
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
6819-6827Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.